Literature DB >> 16227769

Expanding the definition and classification of hypertension.

Thomas D Giles1, Bradford C Berk, Henry R Black, Jay N Cohn, John B Kostis, Joseph L Izzo, Michael A Weber.   

Abstract

Cardiovascular abnormalities are frequently the cause, as well as the effect, of elevated blood pressure. As such, early cardiovascular disease (CVD) may be established before identifiable blood pressure thresholds are crossed. To identify individuals at risk for CVD at an earlier point in the disease process, as well as to avoid labeling persons as hypertensive who are at low risk for CVD, the Hypertension Writing Group proposes incorporating the presence or absence of cardiovascular risk factors, early disease markers, and target organ damage into the definition and classification scheme of hypertension. To describe both the complexity and progressive nature of hypertension, the following definition is proposed: "Hypertension is a progressive cardiovascular syndrome arising from complex and interrelated etiologies. Early markers of the syndrome are often present before blood pressure elevation is observed; therefore, hypertension cannot be classified solely by discrete blood pressure thresholds. Progression is strongly associated with functional and structural cardiac and vascular abnormalities that damage the heart, kidneys, brain, vasculature, and other organs and lead to premature morbidity and death." Classification of hypertension must involve assessing global cardiovascular risk to situate an individual's risk for CVD and events along a continuum. As knowledge of early CVD continues to evolve, the approach to classifying individuals along that continuum can be expected to evolve accordingly. The four categories currently used to classify hypertension are normal, prehypertension, and stages 1 and 2 hypertension. The population identified with prehypertension includes a subgroup with early CVD. We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227769      PMCID: PMC8109641          DOI: 10.1111/j.1524-6175.2005.04769.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  34 in total

Review 1.  Arteries, myocardium, blood pressure and cardiovascular risk: towards a revised definition of hypertension.

Authors:  J N Cohn
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

2.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1984-05

3.  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

Authors: 
Journal:  Arch Intern Med       Date:  1993-01-25

4.  The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study.

Authors:  Mark J Sarnak; Tom Greene; Xuelei Wang; Gerald Beck; John W Kusek; Allan J Collins; Andrew S Levey
Journal:  Ann Intern Med       Date:  2005-03-01       Impact factor: 25.391

5.  The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem.

Authors:  Youfa Wang; Qiong Joanna Wang
Journal:  Arch Intern Med       Date:  2004-10-25

6.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

7.  Trial of preventing hypertension: design and 2-year progress report.

Authors:  Stevo Julius; Shawna Nesbitt; Brent Egan; Niko Kaciroti; M Anthony Schork; Melissa Grozinski; Eric Michelson
Journal:  Hypertension       Date:  2004-07-06       Impact factor: 10.190

8.  Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks.

Authors:  Reinhard Voss; Paul Cullen; Helmut Schulte; Gerd Assmann
Journal:  Int J Epidemiol       Date:  2002-12       Impact factor: 7.196

Review 9.  Arterial stiffness and the systolic hypertension syndrome.

Authors:  Joseph L Izzo
Journal:  Curr Opin Cardiol       Date:  2004-07       Impact factor: 2.161

10.  Blood pressure and end-stage renal disease in men.

Authors:  M J Klag; P K Whelton; B L Randall; J D Neaton; F L Brancati; C E Ford; N B Shulman; J Stamler
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

View more
  66 in total

1.  On redefining hypertension.

Authors:  Michel Accad; Herbert L Fred
Journal:  Tex Heart Inst J       Date:  2010

Review 2.  Monitoring vascular health beyond blood pressure.

Authors:  Daniel A Duprez; Jay N Cohn
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

3.  The continuum of blood pressure risk: when is the best time to intervene?

Authors:  George Bakris
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 4.  Fixed-dose combination lercanidipine/enalapril.

Authors:  Philip I Hair; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Reversion of left ventricle remodeling in spontaneously hypertensive rats by valsartan is associated with the inhibition of caspase-3, -8 and -9 activities.

Authors:  X U Deng; K E Xia; P O Chen; Md Sayed Ali Sheikh; DA-Feng Yang; Si-Min Li; Tian-Lun Yang
Journal:  Biomed Rep       Date:  2015-04-29

6.  Progression of pre-hypertension.

Authors:  Thomas D Giles
Journal:  Curr Hypertens Rep       Date:  2011-08       Impact factor: 5.369

Review 7.  Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

Authors:  Antona J Wagstaff
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  MicroRNAs in hypertension: mechanisms and therapeutic targets.

Authors:  Sándor Bátkai; Thomas Thum
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 9.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Heart failure in hypertension: prevention and treatment.

Authors:  Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos; Javed Butler
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.